NIP
FULC icon

Nicholas Investment Partners’s Fulcrum Therapeutics FULC Stock Holding History

Nicholas Investment Partners’s Portfolio FULC Stock Details FULC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-182,961
Closed -$2.07M – 214
2025
Q4 		$2.07M Buy
+182,961
New +$1.86M 0.15% 153

Other funds holding FULC

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
FTM
First Turn Management Del Mar, California $895M AUM 261.28% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return

Nicholas Investment Partners's FULC Position: Q1 2026 in Review

Nicholas Investment Partners sold out of Fulcrum Therapeutics (FULC) in Q1 2026, closing a stake of 182,961 shares — an estimated $2.07M sold.

Nicholas Investment Partners first reported a position in FULC in Q4 2025 and held it in 1 quarter. The position peaked at $2.07M in Q4 2025. 169 funds tracked by Wall St. Rank hold FULC as of Q1 2026.

  • Nicholas Investment Partners reported no remaining Fulcrum Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Nicholas Investment Partners sold 182,961 Fulcrum Therapeutics shares in Q1 2026, an estimated $2.07M.
  • Nicholas Investment Partners first reported a position in Fulcrum Therapeutics in Q4 2025 and held it in 1 quarter.
  • Nicholas Investment Partners's Fulcrum Therapeutics position peaked at $2.07M in Q4 2025.
  • 169 funds tracked by Wall St. Rank held Fulcrum Therapeutics as of Q1 2026.

Based on Nicholas Investment Partners's 13F filing for Q1 2026, filed 15 May 2026.